MIST News and Press, Milestone Pharmaceuticals Inc. From 08/11/21

Milestone Pharmaceuticals (NASDAQ:MIST): Q2 GAAP EPS of $0.02 beats by $0.28. Revenue of $15M beats by $12M. Shares +2.4%. Press Release For further details see: Milestone Pharmaceuticals EPS beats by $0.28, beats on revenue

Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update Canada NewsWire MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical c...

Research Highlights: Stroke patients were almost twice as likely to be functionally independent (mobile and can perform daily tasks) at 90 days after the stroke if they were treated by a specialized mobile stroke team that traveled to them to perform mechanical clot removal, compared to ...

Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference PR Newswire MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the de...

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreemen...

Milestone Pharmaceuticals ([[MIST]] -1.4%) announces an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia ((PSVT)) and additional cardiov...

Milestone Pharmaceuticals (MIST) announces the data related to key secondary endpoints from its Phase 3 NODE-301 trial of etripamil nasal spray, an investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia ((PSVT)). The data were pres...

Milestone Pharmaceuticals (MIST): Q1 GAAP EPS of -$0.30 beats by $0.03.Cash, cash equivalents and short-term investments of $129.9M.Press Release For further details see: Milestone Pharmaceuticals EPS beats by $0.03

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 Canada NewsWire - Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Canadian pharma small-cap Milestone Pharmaceuticals (NASDAQ: MIST ) has had a tumultuous ride since shares starting trading nearly two years ago. MIST stock was soon going for over $27. It dropped below $2 a share a y...